Nasdaq:ANIX
Anixa Biosciences Inc
A pre-revenue biopharmaceutical developer targeting oncology and rare diseases with a robust pipeline but facing significant burn rates and reliance on external financing.
Key Metrics
Investment Thesis
Bull Case
Investors may view Anixa as a high-potential turnaround story if any of its drug candidates successfully advance through clinical trials and receive regulatory approval. The company's substantial marketable securities portfolio provides a financial buffer that could support operations for an extended period without immediate revenue pressure. A successful partnership deal or licensing agreement could unlock significant value by providing non-dilutive funding and reducing the company's dependency on public market fundraising.
Bear Case
The stock carries extreme downside risk given the consistent widening of operating losses and a massive retained earnings deficit that suggests unsustainable burn without immediate commercial success. The lack of any meaningful revenue stream for over two years indicates the business model has not yet proven its ability to generate self-sustaining cash flows. Investors should also consider the potential for aggressive dilution as management seeks to fund ongoing R&D efforts against a backdrop of shrinking equity base and negative shareholder returns.
About Anixa Biosciences Inc
Anixa Biosciences Inc. is a biopharmaceutical company focused on developing novel therapeutics for unmet medical needs, primarily serving markets in oncology and rare diseases through its proprietary pipeline. The company operates within the high-risk, high-reward biotechnology sector, leveraging extensive R&D efforts to advance drug candidates from preclinical stages to clinical trials. With significant cash reserves but no current revenue generation, the firm relies on strategic partnerships and capital markets to fund its long-term development roadmap.
Analysis
Management Discussion
Management has successfully preserved a positive cash position despite recording net losses exceeding $10 million annually over the past four years, though operating cash flow remains deeply negative at -$7.2 million. The company utilized significant non-cash adjustments including share-based compensation of $3.7 million and common share issuances of $2.4 million to offset its substantial cash burn from R&D and administrative activities. While current assets remain strong at $15.9 million supported by marketable securities, the trajectory indicates a continued need for capital injection or successful milestone achievements to reverse the deteriorating equity position.
Industry Overview
The biotechnology industry is characterized by long development cycles, high failure rates in clinical trials, and significant capital requirements that often result in years of negative earnings before product commercialization. Companies in this space typically rely on venture capital, public equity markets, or strategic partnerships to fund research until a drug candidate reaches late-stage clinical trials. Regulatory approval processes are stringent and lengthy, creating substantial uncertainty regarding the timing and magnitude of future revenue recognition for new therapies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | $210.0K | $210.0K | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | — | $210.0K | $210.0K | $0 |
| Operating Expenses | — | $11.2M | $14.0M | $11.7M |
| Operating Income | $-13.9M | $-11.0M | $-13.8M | $-11.7M |
| R&D | $6.7M | $4.8M | $6.4M | $5.1M |
| G&A | $7.2M | $6.3M | $7.4M | $6.6M |
| Stock-Based Comp | $6.0M | $4.4M | $4.4M | $3.7M |
| Other OpEx | — | $161.0K | $210.0K | $0 |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Income | $104.0K | $1.1M | $1.1M | $673.0K |
| Pre-Tax Income | $-13.9M | $-11.0M | $-13.8M | $-11.7M |
| Income Tax | $-104.0K | $-1.1M | $-1.1M | $-673.0K |
| Continuing Ops | $-13.8M | $-9.9M | $-12.7M | $-11.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-13.8M | $-9.9M | $-12.7M | $-11.0M |
| Minority Interest | $-176.0K | $-119.0K | $-144.0K | $-101.0K |
| Net to Common | $-13.6M | $-9.8M | $-12.6M | $-10.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $30.2M | $25.4M | $21.4M | $15.9M |
| Cash & Equivalents | $12.4M | $915.0K | $1.3M | $1.2M |
| Marketable Securities | $17.3M | $22.9M | $18.7M | $13.9M |
| Prepaid Expenses | $513.0K | $1.2M | $1.3M | $713.0K |
| Other Current Assets | $0 | $270.0K | $173.0K | $0 |
| Long-Term Assets | $212.0K | $166.0K | $229.0K | $193.0K |
| Operating Leases | $212.0K | $166.0K | $229.0K | $193.0K |
| Other LT Assets | $0 | $0 | $0 | $0 |
| Total Assets | $30.4M | $25.5M | $21.6M | $16.1M |
| Current Liabilities | $2.0M | $2.0M | $2.5M | $2.0M |
| Accounts Payable | $265.0K | $206.0K | $525.0K | $165.0K |
| Current Leases | $46.0K | $52.0K | $29.0K | $41.0K |
| Other Current Liab | $0 | $0 | $0 | $0 |
| Long-Term Liabilities | $175.0K | $123.0K | $203.0K | $163.0K |
| LT Operating Leases | $175.0K | $123.0K | $203.0K | $163.0K |
| Other LT Liab | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.2M | $2.2M | $2.7M | $2.1M |
| Shareholders' Equity | $28.2M | $23.4M | $18.9M | $13.9M |
| Paid-In Capital | $247.1M | $252.2M | $260.4M | $266.5M |
| Retained Earnings | $-218.4M | $-228.2M | $-240.8M | $-251.7M |
| Treasury Stock | — | — | $6.0K | — |
| Total L&E | $30.4M | $25.5M | $21.6M | $16.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-13.8M | $-9.9M | $-12.7M | $-11.0M |
| Non-Cash Adjustments | $6.3M | $2.7M | $5.0M | $5.2M |
| Working Capital Changes | $997.0K | $984.0K | $378.0K | $-1.3M |
| Cash from Operations | $-6.5M | $-6.2M | $-7.3M | $-7.2M |
| Cash from Investing | $-10.7M | $-5.6M | $4.3M | $4.9M |
| Share Buybacks | — | — | $6.0K | — |
| Cash from Financing | $452.0K | $366.0K | $3.4M | $2.3M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-16.8M | $-11.4M | $356.0K | $-27.0K |
| Beginning Cash | $29.1M | $12.4M | $915.0K | $1.3M |
| Ending Cash | $12.4M | $915.0K | $1.3M | $1.2M |
Frequently Asked Questions
How does Anixa Biosciences Inc make money?
The company's operations are centered around two primary segments: proprietary drug discovery for cancer indications and research-focused collaborations to advance early-stage therapeutics. Revenue currently derives from limited grant funding or milestone payments, as the firm has not yet generated commercial sales from approved products. The financial structure reflects a pure-play R&D model with substantial investments in general and administrative costs alongside dedicated research and development expenditures.
What are the main risks for ANIX?
The company faces severe liquidity risks given its negative net income and substantial annual operating losses that have widened the retained earnings deficit over recent years. There is significant execution risk associated with the high probability of clinical trial failures common in early-stage biotechnology development. Heavy reliance on equity financing through share issuances may lead to shareholder dilution if additional capital raises are required to sustain operations. The absence of commercial revenue makes the business highly sensitive to macroeconomic conditions affecting investor appetite for speculative biotech stocks.
What is ANIX's competitive advantage?
Anixa possesses a differentiated asset library targeting difficult-to-treat oncology indications where few alternatives exist. The company maintains a lean operational footprint allowing it to extend its cash runway while advancing multiple clinical candidates simultaneously. Strong intellectual property protections around its novel mechanisms of action provide a moat against generic competition in future commercialization phases.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.